CDK4 and breast cancer: Given the lower expression of TAM/Met in HER2+ breast cancer, as expected, we showed that combined TAM/Met and CDK4/6 inhibition exhibited less efficacy in HER2+ breast cancer lines (Figure 3a,b and Supplementary Figure S4a).